Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Abstract Purpose To compare the Response Evaluation Criteria in Solid Tumors (RECIST)
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …

Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen
(PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer …

We aimed to investigate the safety and therapeutic efficacy of radioligand therapy (RLT) of
177Lu-EB-prostate-specific membrane antigen (PSMA) in patients with metastatic castration …

CT and bone scintigraphy are not useful for response evaluation of bone metastases to
223Ra treatment in metastatic castration-resistant prostate cancer (mCRPC). PET using …

Quantitative evaluation of prostate-specific membrane antigen (PSMA)–targeting PET/CT
remains challenging but is urgently needed for the use of standardized PET-based response …

At present, little is known about the molecular imaging-based response assessment of
prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lutetium …